Notably, TRPC6 knockdown had no effect on tubulointerstitial inflammation and fibrosis in autoimmune glomerulonephritis and aging rats, although it significantly reduced glomerular sclerosis (Kim et al., 2019; Kim and Dryer, 2021), indicating that targeting TRPC6 may have disease specificity in the treatment of glomerular diseases. Here, TRPC6 is linked to Glomerular sclerosis.